Dr. Andrew Hill: “The first-line use of TDF/3TC/DTG leads to lower risks of clinical obesity than combinations like TAF/FTC/DTG or TAF/FTC/BIC, or dual therapies like DTG/3TC”
Dr. Andrew Hill, MD, is a senior visiting Research Fellow in the Pharmacology Department at Liverpool University. His main research is on antiretroviral treatment for developing countries. He is an advisor to the Clinton Foundation and the Bill and Melinda Gates Foundation, designing clinical trial programs of dose optimization for antiretrovirals. Dr. Hill is graduated from Oxford [...]